Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Daniel Lucas Kerr"'
Autor:
Johannes R. Kratz, Robert C. Doebele, Collin M. Blakely, Jonathan W. Riess, Daniel Lucas Kerr, Matthew A. Gubens, Julia K Rotow, Kirk D. Jones, Anatoly Urisman, Tejas Patil, Erin L. Schenk, Bianca Bacaltos, S. Joo, Dara L. Aisner, Trever G. Bivona, David M. Jablons, Wei Wu
Publikováno v:
Journal of Thoracic Oncology. 16:S1039-S1040
Autor:
Brandon Rule, Collin M. Blakely, Julian Downward, Charles Swanton, Subramanian Venkatesan, Beatrice Gini, Nnennaya Kanu, Elizabeth A. Yu, William Hill, Manasi K. Mayekar, Bjorn Bakker, Ai Nagano, Shigeki Nanjo, Andrew Rowan, Philippe Gui, Lindsay K. Larson, Carlos Martinez Ruiz, Reuben S. Harris, Emily K. Law, Daniel Lucas Kerr, Deborah R. Caswell, Nuri A. Temiz, Su Kit Chew, Franziska Haderk, Christopher I. Moore, Natalie I. Vokes, Sebastijan Hobor, Wei Wu, Prokopios P. Argyris, Michelle Dietzen, Johnny Yu, Rachel Isaksson Vogel, Bruna Almeida, Carlos Gomez, Trever G. Bivona, Eliezer M. Van Allen, Maise Al Bakir, Cameron Durfee, Julia K Rotow, Nicholas J. Thomas, Eva Grönroos, Lisa Tan, Nicholas McGranahan, Lauren Cech, William L. Brown, Miguel M. Murillo, Caroline E. McCoach, Joanna Przewrocka
Introductory paragraphThe clinical success of targeted cancer therapy is limited by drug resistance that renders cancers lethal in patients1-4. Human tumours can evolve therapy resistance by acquiringde novogenetic alterations and increased heterogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e88669dbc506986684565de05cabf66a
https://doi.org/10.1101/2020.12.18.423280
https://doi.org/10.1101/2020.12.18.423280